AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

Throughout the past few days, AstraZeneca has been presenting data at the American Society of Clinical Oncology (ASCO) Annual meeting that reaffirms the company’s commitment to redefine cancer care.

In a pre-ASCO panel co-led by The Cancer Support Community, AstraZeneca asked the million-dollar question: Are we ready to talk cure in cancer? While the panelists, which included oncologists, researchers and AstraZeneca executives, didn’t come to a clear conclusion, the company is making headway in at least two indications: post-surgery, high-risk HER2-negative early breast cancer and chronic lymphocytic leukemia (CLL).